TME Pharma N.V. (EPA:ALTME)
France · Delayed Price · Currency is EUR 0.0892
+0.0014 (1.59%)
Aug 21, 2026, 5:35 PM CET
TME Pharma Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2.01 | 3.24 | 2.25 | 4.63 | 9.46 |
Cash & Short-Term Investments | 2.01 | 3.24 | 2.25 | 4.63 | 9.46 |
Cash Growth | -37.90% | 44.32% | -51.55% | -50.99% | -8.23% |
Accounts Receivable | 0 | - | - | - | - |
Other Receivables | 0.02 | 0.03 | 0.04 | 0.28 | 0.08 |
Receivables | 0.02 | 0.03 | 0.04 | 0.28 | 0.08 |
Prepaid Expenses | 0.08 | 0.07 | 0.08 | 0.06 | 0.1 |
Restricted Cash | - | 0.01 | 0.01 | 0.01 | 0.03 |
Other Current Assets | 0.01 | 0.02 | 0.01 | 0.02 | 0.03 |
Total Current Assets | 2.12 | 3.36 | 2.39 | 5.01 | 9.69 |
Property, Plant & Equipment | 0.01 | 0.03 | 0.1 | 0.22 | 0.07 |
Long-Term Investments | 0.01 | 0.01 | 0.01 | - | - |
Other Intangible Assets | 0 | 0 | 0 | 0 | 0 |
Other Long-Term Assets | - | - | - | 0.01 | 0.01 |
Total Assets | 2.14 | 3.41 | 2.49 | 5.24 | 9.77 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.8 | 1.33 | 1.17 | 1.7 | 2.24 |
Accrued Expenses | 0.26 | 0.4 | 0.33 | 0.48 | 0.48 |
Short-Term Debt | 2.39 | - | - | - | - |
Current Portion of Long-Term Debt | - | - | 1.1 | 3.91 | 2.42 |
Current Portion of Leases | - | - | 0.07 | 0.11 | 0.02 |
Other Current Liabilities | 0.27 | 0.06 | 0.12 | 0.25 | 0.11 |
Total Current Liabilities | 3.72 | 1.79 | 2.79 | 6.45 | 5.27 |
Long-Term Leases | - | - | - | 0.07 | - |
Total Liabilities | 3.72 | 1.79 | 2.79 | 6.51 | 5.27 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.94 | 0.94 | 0.17 | 1.74 | 0.75 |
Additional Paid-In Capital | 201.07 | 200.98 | 194.12 | 184.84 | 176.46 |
Retained Earnings | -203.38 | -200.09 | -194.37 | -187.64 | -172.5 |
Treasury Stock | -0.22 | -0.23 | -0.22 | -0.22 | -0.19 |
Comprehensive Income & Other | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Total Common Equity | -1.58 | 1.61 | -0.29 | -1.27 | 4.52 |
Minority Interest | - | - | - | - | -0.01 |
Shareholders' Equity | -1.58 | 1.61 | -0.29 | -1.27 | 4.5 |
Total Liabilities & Equity | 2.14 | 3.41 | 2.49 | 5.24 | 9.77 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2.39 | - | 1.17 | 4.09 | 2.44 |
Net Cash (Debt) | -0.38 | 3.24 | 1.08 | 0.55 | 7.02 |
Net Cash Growth | - | 200.28% | 96.90% | -92.19% | -27.30% |
Net Cash Per Share | -0.00 | 0.09 | 0.21 | 0.47 | 10.63 |
Filing Date Shares Outstanding | 94.2 | 94.11 | 17.28 | 1.72 | 0.84 |
Total Common Shares Outstanding | 94.2 | 94.11 | 17.28 | 1.72 | 0.75 |
Working Capital | -1.6 | 1.57 | -0.4 | -1.44 | 4.43 |
Book Value Per Share | -0.02 | 0.02 | -0.02 | -0.74 | 6.06 |
Tangible Book Value | -1.58 | 1.61 | -0.3 | -1.28 | 4.51 |
Tangible Book Value Per Share | -0.02 | 0.02 | -0.02 | -0.74 | 6.05 |
Machinery | 0.23 | 0.32 | 0.36 | 0.35 | 0.36 |